Zobrazeno 1 - 10
of 29
pro vyhledávání: '"H.W. Christinger"'
Autor:
Arieh Gertler, H.W. Christinger, P.A. Elkins, Anthony A. Kossiakoff, E. Sakal, Y. Sandowski, A.M. de Vos
Publikováno v:
Nature Structural Biology. 7:808-815
Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::794bb80cceaebc08483ec5a21969de5f
https://doi.org/10.1038/79047
https://doi.org/10.1038/79047
Autor:
Germaine Fuh, Christian Wiesmann, H.W. Christinger, Yongmei Chen, Henry B. Lowman, A.M. de Vos, P. Mckay, Bing Li
Publikováno v:
Journal of Molecular Biology. 293:865-881
The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEGF) to vascular endothelial growth factor (VEGF) has been affinity-matured through complementarity-determining region (CDR) mutation, followed by affinity selection using mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff2556b5b0e599a216794a12eccaf516
https://doi.org/10.1006/jmbi.1999.3192
https://doi.org/10.1006/jmbi.1999.3192
Autor:
Sarah G. Hymowitz, H.W. Christinger, Mark P. O'Connell, A.M. de Vos, Germaine Fuh, Robert F. Kelley, M.H. Ultsch, Avi Ashkenazi
Publikováno v:
Molecular Cell. 4(4):563-571
Formation of a complex between Apo2L (also called TRAIL) and its signaling receptors, DR4 and DR5, triggers apoptosis by inducing the oligomerization of intracellular death domains. We report the crystal structure of the complex between Apo2L and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6536c8e47ef95d595401f8bf0d0438f7
Autor:
Brian C. Cunningham, C.J. Keenan, Wayne J. Fairbrother, Andrea G. Cochran, Christian Wiesmann, H.W. Christinger, A.M. de Vos, Gloria Meng
Publikováno v:
Biochemistry. 37:17765-17772
Vascular endothelial growth factor (VEGF) is a specific and potent angiogenic factor and, therefore, a prime therapeutic target for the development of antagonists for the treatment of cancer. As a first step toward this goal, phage display was used t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14094e1ac778aff59c3bc1e4f99bd19f
https://doi.org/10.1021/bi9819327
https://doi.org/10.1021/bi9819327
Autor:
Germaine Fuh, Jeffrey Tom, Clifford Quan, Stephanie Shriver, Wayne J. Fairbrother, Christopher J. Keenan, Andrea G. Cochran, Brian C. Cunningham, James A. Wells, H.W. Christinger
Publikováno v:
Biochemistry. 37:17754-17764
Peptides that inhibit binding of vascular endothelial growth factor (VEGF) to its receptors, KDR and Flt-1, have been produced using phage display. Libraries of short disulfide-constrained peptides yielded three distinct classes of peptides that bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b430669b7bf76ff732ee731eb33530a7
https://doi.org/10.1021/bi981931e
https://doi.org/10.1021/bi981931e
Publikováno v:
Structure. 6:637-648
Background: Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and is a potent angiogenic and vascular permeabilizing factor. VEGF is also an important mediator of pathological angiogenesis associated with cancer, rheum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b0436690a4230144c51fd98b5eec8f
https://doi.org/10.1016/s0969-2126(98)00065-3
https://doi.org/10.1016/s0969-2126(98)00065-3
Publikováno v:
Structure. 5:1325-1338
Background: Vascular endothelial growth factor (VEGF) is an endothelial cell-specific angiogenic and vasculogenic mitogen. VEGF also plays a role in pathogenic vascularization which is associated with a number of clinical disorders, including cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b704a3627d765123e513d9b6bdd7c08c
https://doi.org/10.1016/s0969-2126(97)00284-0
https://doi.org/10.1016/s0969-2126(97)00284-0
Autor:
Bruce Keyt, Lea T. Berleau, Napoleone Ferrara, Brian C. Cunningham, Yves A. Muller, H.W. Christinger, Abraham M. de Vos
Publikováno v:
Proteins: Structure, Function, and Genetics. 26:353-357
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor with a unique specificity for vascular endothelial cells. In addition to its role in vasculogenesis and embryonic angiogenesis, VEGF is implicated in pathologic neovascularizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b1d724054ed9d256186648ab035aef8
https://doi.org/10.1002/(sici)1097-0134(199611)26:3<353::aid-prot9>3.0.co
https://doi.org/10.1002/(sici)1097-0134(199611)26:3<353::aid-prot9>3.0.co
Publikováno v:
The Journal of biological chemistry. 279(11)
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family and plays an important role in pathological angiogenic events. PlGF exerts its biological activities through binding to VEGFR1, a receptor tyrosine kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::852400629ffbd6bee79dd4fad5e0f47b
https://pubmed.ncbi.nlm.nih.gov/14684734
https://pubmed.ncbi.nlm.nih.gov/14684734
Autor:
Anthony A. Kossiakoff, Y. Sandowski, E. Sakal, Arieh Gertler, P.A. Elkins, H.W. Christinger, A.M. de Vos
Publikováno v:
Acta crystallographica. Section D, Biological crystallography. 54(Pt 6 Pt 2)
Growth hormone and prolactin control somato-lactogenic biology. While high-resolution crystal structures have been determined for receptor complexes of human growth hormone, no such information exists for prolactin. A stable 1:2 complex was formed be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f441a06a94dd440f5a4bcdaf55945d
https://pubmed.ncbi.nlm.nih.gov/10089521
https://pubmed.ncbi.nlm.nih.gov/10089521